John G. Compton - 17 Feb 2026 Form 3 Insider Report for 20/20 Biolabs, Inc.

Reporting relationship
Director
Issuer ticker
AIDX on Nasdaq
Reported as of
17 Feb 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
17 Feb 2026, 18:28:25 UTC
Next SEC filing
23 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John G. Compton

Key filing fact

John G. Compton filed Form 3 for 20/20 Biolabs, Inc. on 17 Feb 2026.

Key facts

  • This page summarizes John G. Compton's Form 3 filing for 20/20 Biolabs, Inc..
  • 0 reported transactions and 7 derivative rows are listed below.
  • Accepted by SEC: 17 Feb 2026, 18:28.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002107487 Primary reporting owner

Compton John G.

Relationship
Director
Address
C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG
Signature
/s/ John G. Compton
Signature date
17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
6,666
Date
17 Feb 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker holding Derivative

Series A-2 Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,669
Exercise price
Footnotes
F1
No ticker holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
48,780
Exercise price
$0.8200
Footnotes
F2
No ticker holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
76,628
Exercise price
$1.04
Footnotes
F3
No ticker holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
37,584
Exercise price
$1.06
Footnotes
F4
No ticker holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
37,583
Exercise price
$1.06
Footnotes
F5
No ticker holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$1.74
Footnotes
F6
No ticker holding Derivative

Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$2.55
Footnotes
F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Each share of series A-2 preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A-2 preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A-2 preferred stock has no expiration date.

Footnote F2

On August 1, 2019, the Reporting Person was granted a stock option for the purchase of 48,780 shares of common stock, which vested in full on the date of grant.

Footnote F3

On January 28, 2021, the Reporting Person was granted a stock option for the purchase of 76,628 shares of common stock, which vested in full on the date of grant.

Footnote F4

On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,584 shares of common stock, which vested in equal monthly installments over 12 months.

Footnote F5

On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,583 shares of common stock, which vested in full on the date of grant.

Footnote F6

On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.

Footnote F7

On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .